The Lancet Mitochondrial Peptides: MOTS-c, SS-31, and the Future of Longevity Research

Lancet Insights | 2026-07-11 | 13 min read

Analysis of mitochondrial-derived peptides including MOTS-c and SS-31 (elamipretide) for longevity research, covering metabolic regulation, ATP production, oxidative stress, and age-related disease intervention.

Mitochondrial Peptides: A New Frontier in Longevity Research

The mitochondria, long recognised as the powerhouse of the cell, have emerged as central targets for anti-aging interventions. Research published in The Lancet and Nature has identified novel mitochondrial-derived peptides (MDPs) as key regulators of metabolic homeostasis and aging processes.

MOTS-c: The Mitochondrial Metabokine

Discovery and Structure

MOTS-c was discovered in 2015 as the first mitochondrial-encoded secreted peptide:

Sequence: MTRDIVDALTAAMAQN

This 16-amino acid peptide is derived from the mitochondrial 12S rRNA region and functions as a metabokine—signalling molecule that regulates cellular metabolism.

Metabolic Effects

MOTS-c demonstrates significant metabolic benefits:

#### Insulin Sensitisation

  • Improves insulin sensitivity in muscle tissue
  • Activates AMPK pathway
  • Enhances glucose uptake in skeletal muscle
  • Reduces insulin resistance in high-fat diet models

#### Metabolic Regulation

  • Increases fatty acid oxidation
  • Reduces hepatic steatosis
  • Improves glucose tolerance
  • Enhances metabolic flexibility

Exercise Mimetic Properties

MOTS-c is termed an "exercise mimetic" because it recapitulates key benefits of exercise:

  • Increased energy expenditure
  • Improved insulin sensitivity
  • Enhanced fatty acid oxidation
  • Promotion of mitochondrial biogenesis

Research suggests MOTS-c may be particularly effective in age-related metabolic decline.

Age-Related Research

Studies in aged mice demonstrate MOTS-c:

  • Restores youthful metabolic parameters
  • Improves physical performance
  • Reverses age-related insulin resistance
  • Extends healthspan metrics

SS-31 (Elamipretide): Mitochondrial Protector

Structure and Mechanism

SS-31 (also known as elamipretide) is a mitochondria-targeted tetrapeptide:

Sequence: D-Arg-Dmt-Lys-Phe-NH2

Where Dmt = 2',6'-dimethyltyrosine

The peptide selectively binds to cardiolipin on the inner mitochondrial membrane:

  • Stabilises mitochondrial cristae structure
  • Improves electron transport chain efficiency
  • Reduces ROS production
  • Maintains mitochondrial membrane potential

Clinical Research

SS-31 has undergone extensive clinical investigation:

#### Heart Failure

  • Phase 2 trials in heart failure with reduced ejection fraction (HFrEF)
  • Improved symptoms and exercise capacity
  • Enhanced mitochondrial function markers
  • Phase 3 ENTRESTO-SYMBIO trial ongoing

#### Mitochondrial Myopathy

  • Phase 2/3 trials in primary mitochondrial myopathy (MM)
  • Improved NMDAS (Neurological Mild Disability Scale) scores
  • Enhanced 6-minute walk distance
  • FDA breakthrough therapy designation

#### Other Indications

Research is expanding to:

  • Dry age-related macular degeneration
  • Acute kidney injury
  • Sepsis-induced organ dysfunction
  • Peripheral artery disease

Mitochondrial Biogenesis

SIRT1/PGC-1α Pathway

Both MOTS-c and SS-31 affect mitochondrial biogenesis through:

  • SIRT1 activation
  • PGC-1α deacetylation
  • NRF1/2 activation
  • TFAM upregulation
  • Increased mitochondrial DNA copy number

Quality Sourcing Requirements

Mitochondrial research requires high-purity peptides:

  • HPLC purity ≥99.5%
  • Mass spectrometry sequence verification
  • Endotoxin testing (especially for in vivo)
  • Batch-specific COA documentation
  • Proper storage (-20°C)
  • Reconstitution with appropriate solvents

Combination Approaches

Synergistic Mechanisms

MOTS-c and SS-31 may complement each other:

  • MOTS-c: Metabolic signalling and insulin sensitisation
  • SS-31: Structural mitochondrial protection
  • Combined: Comprehensive mitochondrial support

Research Protocols

Current research combinations include:

  • MOTS-c + exercise training
  • SS-31 + standard heart failure therapy
  • Both peptides with caloric restriction mimetics
  • Peptide combinations with NAD+ precursors

Future Directions

Personalized Mitochondrial Medicine

Emerging research suggests:

  • Genetic variants affecting mitochondrial function
  • Age-related mitochondrial decline patterns
  • Individual response variability
  • Biomarker-guided therapy

Novel Mitochondrial Peptides

Discovery continues with:

  • Humanin and analogues
  • SHLP1-6 (small humanin-like peptides)
  • Novel MDPs yet to be characterised
  • Mitochondrial-derived signal peptides

Research Applications

In Vitro Studies

MOTS-c concentrations: 0.1-10 μM in cell culture SS-31 concentrations: 0.01-1 μM in cell culture

Endpoints measured:

  • Oxygen consumption rate (OCR)
  • ATP production
  • Mitochondrial membrane potential
  • ROS production
  • Metabolic flux

In Vivo Research

Rodent dosing:

  • MOTS-c: 1-10 mg/kg intraperitoneal or subcutaneous
  • SS-31: 1-3 mg/kg subcutaneous infusion or injection

Models used:

  • High-fat diet-induced obesity
  • Aged mice (18-24 months)
  • Myocardial infarction models
  • Mitochondrial disease models

ZePeptide provides research-grade MOTS-c and SS-31 with complete analytical documentation for mitochondrial and longevity research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides